[1] Webert LK, Schantell M, Horne LK, John JA, Glesinger R, O’Neill J, et al. Motor-related neural dynamics are modulated by regular cannabis use among people with HIV. J Neuroimmune Pharmacol. 2025;20(1):63.

[2] Balant M, Gras A, Ruz M, Vallès J, Vitales D, Garnatje T. Traditional uses of cannabis: An analysis of the CANNUSE database. J Ethnopharmacol. 2021;279:114362.

[3] Wang Q, Qin Z, Xing X, Zhu H, Jia Z. Prevalence of cannabis use around the world: A systematic review and meta-analysis, 2000–2024. China CDC Wkly. 2024;6(25):597–604.

[4] Hidding U, Mainka T, Buhmann C. Therapeutic use of medical cannabis in neurological diseases: A clinical update. J Neural Transm. 2024;131(2):117–26.

[5] Touw M. The religious and medicinal uses of Cannabis in China, India and Tibet. J Psychoactive Drugs. 1981;13(1):23–34.

[6] Connor JP, Stjepanović D, Le Foll B, Hoch E, Budney AJ, Hall WD. Cannabis use and cannabis use disorder. Nat Rev Dis Primers. 2021;7(1):16.

[7] Rafei P, Englund A, Lorenzetti V, Elkholy H, Potenza MN, Baldacchino AM. Transcultural aspects of cannabis use: A descriptive overview of cannabis use across cultures. Curr Addict Rep. 2023;10(3):458–471.

[8] Alves Jesus CH, Volpe J, Sotomaior BB, Barbosa MA, Ferreira MV, Fiatcoski F, et al. Morphineinduced side effects can be differentially modulated by cannabidiol in male and female rats. Behav Pharmacol. 2025;36(1):1–15.

[9] Rubin-Kahana D, Matheson J, Mielnik CA, Knight R, Wright M, Marley N, et al. Sex and gender influences on problematic cannabis use and cannabis use disorder: A scoping review protocol. medRxiv. 2025;2025-06.

[10] Gorey C, Kuhns L, Smaragdi E, Kroon E, Cousijn J. Age-related differences in the impact of cannabis use on the brain and cognition: A systematic review. Eur Arch Psychiatry Clin Neurosci. 2019;269(1):37– 58.

[11] Skumlien M, Langley C, Sahakian BJ. Is cannabis use associated with motivation? A review of recent acute and non-acute studies. Curr Behav Neurosci Rep. 2024;11(1):33–43.

[12] Hoch E, Volkow ND, Friemel CM, Lorenzetti V, Freeman TP, Hall W. Cannabis, cannabinoids and health: A review of evidence on risks and medical benefits. Eur Arch Psychiatry Clin Neurosci. 2025;275(2):281– 292.

[13] Gliksberg O, Livne O, Lev-Ran S, Rehm J, Hasson- Ohayon I, Feingold D. The association between cannabis use and perceived social support: The mediating role of decreased social network. Int J Ment Health Addict. 2022;20(5):2799–2812.

[14] Arboleda MF, Prosk E. Practical recommendations for the use of medical cannabis. In: Arboleda MF, Prosk E, ed. Cannabinoids and pain. Cham: Springer; 2021. pp. 153–165.

[15] Calapai F, Cardia L, Esposito E, Ammendolia I, Mondello C, Lo Giudice R, et al. Pharmacological aspects and biological effects of cannabigerol and its synthetic derivatives. Evid Based Complement Alternat Med. 2022;2022(1):3336516.

[16] Lindner T, Schmidl D, Peschorn L, Pai V, Popa- Cherecheanu A, Chua J, et al. Therapeutic potential of cannabinoids in glaucoma. Pharmaceuticals (Basel). 2023;16(8):1149.

[17] Wang MT, Danesh-Meyer HV. Cannabinoids and the eye. Surv Ophthalmol. 2021;66(2):327–345.

[18] Katsimpris A, Baumeister SE, Baurecht H, Tatham AJ, Nolde M. Cannabis use and the risk of primary open-angle glaucoma: A Mendelian randomization study. Sci Rep. 2023;13(1):19605.

[19] Aebersold A, Duff M, Sloan L, Song ZH. Cannabidiol signaling in the eye and its potential as an ocular therapeutic agent. Cell Physiol Biochem. 2021;55(S5 Suppl 5):1–14.

[20] Bondok M, Nguyen AX, Lando L, Wu AY. Adverse ocular impact and emerging therapeutic potential of cannabis and cannabinoids: A narrative review. Clin Ophthalmol. 2024;18:3529–3556.

[21] Manning B, Downey LA, Narayan A, Hayley AC. A systematic review of oculomotor deficits associated with acute and chronic cannabis use. Addict Biol. 2024;29(1):e13359.

[22] McDonald AJ, Doggett A, Belisario K, Gillard J, De Jesus J, Vandehei E, et al. Cannabis use and misuse following recreational cannabis legalization. JAMA Netw Open. 2025;8(4):e256551.

[23] Ortiz-Peregrina S, Ortiz C, Casares-López M, Jiménez JR, Anera RG. Effects of cannabis on visual function and self-perceived visual quality. Sci Rep. 2021;11(1):1655.

[24] Casares-López M, Ortiz-Peregrina S, Castro-Torres JJ, Ortiz C, Martino F, Jiménez JR. Assessing the influence of cannabis and alcohol use on different visual functions: A comparative study. Exp Eye Res. 2022;224:109231.

[25] 24. Ortiz-Peregrina S, Oviedo-Trespalacios O, Ortiz C, Anera RG. Self-regulation of driving behavior under the influence of cannabis: the role of driving complexity and driver vision. Hum Factors. 2023 Nov;65(7):1506–24.

[26] Ortiz-Peregrina S, Martino F, Casares-López M, Granados-Delgado P, Anera RG, Castro Torres JJ. Visual function and vehicle driving performance under the effects of cannabidiol: A randomized cross-over experiment. Addiction. 2025;120(5):975– 983.

[27] Polli L, Schwan R, Albuisson E, Malbos L, Angioi- Duprez K, Laprevote V, et al. Oscillatory potentials abnormalities in regular cannabis users: Amacrine cells dysfunction as a marker of central dopaminergic modulation. Prog Neuropsychopharmacol Biol Psychiatry. 2021;108:110083.

[28] Cheyne K, Niederer RL, Ambler A, Barrett-Young A, Guiney H, Poulton R, et al. Persistent cannabis use and ocular health in midlife. Am J Prev Med. 2025;69(4):107955.

[29] Zhang Z, Li R, Lu H, Zhang X. Systemic administration with tetrahydrocannabinol causes retinal damage in BALB/c mice. Hum Exp Toxicol. 2020;39(3):290– 300.

[30] Duhachek A, Coughlan AT, Iacobucci D. Results on the standard error of the coefficient alpha index of reliability. Mark Sci. 2005;24(2):294–301.

[31] Zimmerman DW. Test reliability and the Kuder- Richardson formulas: Derivation from probability theory. Educ Psychol Meas. 1972;32(4):939–954.

[32] Lynskey MT, Fergusson DM, Horwood LJ. The origins of the correlations between tobacco, alcohol, and cannabis use during adolescence. J Child Psychol Psychiatry. 1998;39(7):995–1005.

[33] World Health Organization Regional Office for Europe. Alcohol, e-cigarettes, cannabis: Concerning trends in adolescent substance use – WHO/Europe report. Copenhagen: WHO; 2024.

[34] Hamaoui J, Pocuca N, Ditoma M, Héguy C, Simard C, Aubin R, et al. Age of onset of cannabis use and substance use problems: A systematic review of prospective studies. Addict Behav. 2025;163:108259.

[35] Chadwick B, Miller ML, Hurd YL. Cannabis use during adolescent development: Susceptibility to psychiatric illness. Front Psychiatry. 2013;4:129.

[36] Fergusson DM, Swain-Campbell NR, Horwood LJ. Arrests and convictions for cannabis related offences in a New Zealand birth cohort. Drug Alcohol Depend. 2003;70(1):53–63.

[37] Lynskey MT, Coffey C, Degenhardt L, Carlin JB, Patton G. A longitudinal study of the effects of adolescent cannabis use on high school completion. Addiction. 2003;98(5):685–692.

[38] Degenhardt L, Coffey C, Carlin JB, Swift W, Moore E, Patton GC. Outcomes of occasional cannabis use in adolescence: 10-year follow-up study in Victoria, Australia. Br J Psychiatry. 2010;196(4):290–295.

[39] Scheyer AF, Laviolette SR, Pelissier AL, Manzoni OJ. Cannabis in adolescence: Lasting cognitive alterations and underlying mechanisms. Cannabis Cannabinoid Res. 2023;8(1):12–23.

[40] Taylor M, Collin SM, Munafò MR, MacLeod J, Hickman M, Heron J. Patterns of cannabis use during adolescence and their association with harmful substance use behaviour: Findings from a UK birth cohort. J Epidemiol Community Health. 2017;71(8):764–770.

[41] Osborne KJ, Barch DM, Jackson JJ, Karcher NR. Psychosis spectrum symptoms before and after adolescent cannabis use initiation. JAMA Psychiatry. 2025;82(2):181–190.

[42] Gowin JL, Ellingson JM, Karoly HC, Manza P, Ross JM, Sloan ME, et al. Brain function outcomes of recent and lifetime cannabis use. JAMA Netw Open. 2025;8(1):e2457069.

[43] Fergusson DM, Horwood LJ. Does cannabis use encourage other forms of illicit drug use? Addiction. 2000;95(4):505–520.

[44] Degenhardt L, Hall W, Lynskey M. The relationship between cannabis use and other substance use in the general population. Drug Alcohol Depend. 2001;64(3):319–327.

[45] Myran DT, Pugliese M, McDonald AJ, Xiao J, Fischer B, Finkelstein Y, et al. Cannabis use disorder emergency department visits and hospitalizations and 5-year mortality. JAMA Netw Open. 2025;8(2):e2457852.

[46] Durand L, O’Kane A, Maguire R, Ryan A, Cusack D, Keenan E, et al. Drug and polydrug detection in drivers suspected of driving under the influence of an intoxicant in Ireland 2012-2018: A national repeated cross-sectional study. Traffic Inj Prev. 2025:1–9.

[47] Auguste ME, Pawelzik J, Scholz C. Integrating crash and fluids toxicology data to examine injury outcomes and associated driver behaviors. Accid Anal Prev. 2025;221:108200.

[48] Miller BP, Aston ER, Spindle TR, Amlung M. Pass the keys: Using behavioral economics to explore driving after cannabis use. Subst Use Addctn J. 2026;47(1):134–143.

[49] Hoch E, Bonnet U, Thomasius R, Ganzer F, Havemann-Reinecke U, Preuss UW. Risks associated with the non-medicinal use of cannabis. Dtsch Arztebl Int. 2015;112(16):271–278.

[50] Desai R, Jain A, Sultan W, Gandhi Z, Raju AR, Varughese VJ, et al. Hypertensive crisis-related hospitalizations and subsequent major adverse cardiac events in young adults with cannabis use disorder: a nationwide analysis. Medicina. 2022;58(10):1465.

[51] Testai FD, Gorelick PB, Aparicio HJ, Filbey FM, Gonzalez R, Gottesman RF, et al.; American Heart Association Stroke Brain Health Science Subcommittee of the Stroke Council; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular and Stroke Nursing; Council on Lifestyle and Cardiometabolic Health; and Council on Peripheral Vascular Disease. Use of marijuana: Effect on brain health: A scientific statement from the American Heart Association. Stroke. 2022;53(4):e176–187.

[52] Lyons CJ, Robson AG. Retinal ganglion cell dysfunction in regular cannabis users: Is the evidence strong enough to consider an association? JAMA Ophthalmol. 2017;135(1):60–61.

[53] Winton-Brown TT, Allen P, Bhattacharyya S, Borgwardt SJ, Fusar-Poli P, Crippa JA, et al. Modulation of auditory and visual processing by delta-9- tetrahydrocannabinol and cannabidiol: An FMRI study. Neuropsychopharmacology. 2011;36(7):1340– 1348.

[54] Mikulskaya E, Martin FH. Contrast sensitivity and motion discrimination in cannabis users. Psychopharmacology. 2018;235(8):2459–2469.

[55] Klumpers LE, Cole DM, Khalili-Mahani N, Soeter RP, Te Beek ET, Rombouts SA, et al. Manipulating brain connectivity with δ⁹-tetrahydrocannabinol: A pharmacological resting state FMRI study. Neuroimage. 2012;63(3):1701–1711.